Q BioMed Inc (OTCMKTS:QBIO) can boast a jump as high as 25% over the last 5 days, but as we know bio-techs at this stage are prone to volatility. Over the last month, the stock is down over 19%. What gives with QBIO? The answer may offer a window into how the market is evaluating early-stages biotechs. The typical measure of biotechs value propositions is the catalysts and potential in their technology and the data in their pipeline of assets – test results, patient trials, or the like. But, while QBIO seems to check all the right boxes, their chart continues to be uninspiring. However, all that could change with some upcoming catalysts and licensing deals.
While the price action is not there for QBIO, the volume has started to spike upward. The driver for this interest could be two recent bits of news. First, a Glaucoma-tech licensing deal with Washington University. Next, the progression of Strontium Chloride 89.
Q BioMed Inc (OTCMKTS:QBIO) bills itself as a biomedical acceleration and development company in the United States. The company focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Its primary target indication is for a therapeutic eye-drop for the treatment of glaucoma in adults. The company’s lead candidate is MAN-01.
The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York. QBIO is a biomedical acceleration and development company. The Company is focused on licensing and acquiring biomedical assets across the healthcare spectrum. QBIO is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
According to company materials, QBIO “is an acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.”
Find out when $QBIO stock reaches critical levels. Subscribe to FinanceRegistrar.com Right Now by entering your Email in the box below.
According to the company, QBIO will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.
“The ophthalmology in general and glaucoma sector specifically are currently in an active consolidation and business development cycle. Having access to a truly innovative technology that compliments ours as a companion diagnostic could greatly enhance the value of the Mannin Research MAN-01 technology. We are excited to evaluate this technology and look forward to a new collaborative partnership with a leading institution like Washington University School of Medicine,” said Denis Corin, CEO of Q BioMed, Inc.
Meanwhile, Strontium 89 is the only FDA approved generic version and is reimbursable by Medicare and private insurers. In the United States alone, 450,000 individuals diagnosed with breast or prostate cancer develop bone metastases, a common cause of pain that Strontium strives to address. “Clinical studies at leading medical centers around the world have demonstrated that patient survivals may be extended using Strontium-89 in combination with other agents. Additional therapeutic indications for Strontium 89 are possible, and we intend to pursue this objective in 2018,” QBIO said in a statement.
Q BioMed Inc (OTCMKTS:QBIO) has a market cap of $48.58M with a float of 7.48M. Also, and important to note, the company just raised a cool $5.48M. There is a lot to like in the portfolio of QBIO and if anything clicks here, they could see another big spike ahead. For continuing coverage on shares of $QBIO stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!